GH Diaconesses Croix Saint-Simon
Welcome,         Profile    Billing    Logout  
 9 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DUBREUIL, Olivier
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Completed
3
507
Europe, RoW
Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid
Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group
OESOPHAGO-GASTRIC CARCINOMA
02/25
02/25
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
AQUATIC, NCT04217447: Assessment of Quitting Versus Using Aspirin Therapy in Patients Treated with Oral Anticoagulation for Atrial Fibrillation or Other Indication with Stabilized Coronary Artery Disease

Terminated
3
874
Europe
OAC + Aspirin 100mg od, OAC + placebo of Aspirin 100mg od
University Hospital, Brest, Bayer
Coronary Artery Disease
10/24
10/24
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting
2
99
Europe
MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil
GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG
Anal Cancer
02/23
12/24
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting
2
55
Europe
Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab
Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
09/24
09/24
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting
2
400
Europe
FOLFOX regimen, CAPOX regimen
UNICANCER
Digestive Cancer, Colorectal Cancer
04/27
01/30
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
2
73
Europe
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
10/26
10/28
PREMICES, NCT06646445: Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: Study.

Not yet recruiting
2
60
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Watch-and-wait approach, Surgery, Adjuvant chemotherapy
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Colon Cancer
12/27
12/29
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
BETTER 2, NCT03351296 / 2017-000741-46: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting
2
140
Europe
LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pancreatic Cancer
12/28
12/28
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting
2
78
Europe
Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Neuroendocrine Carcinoma, Digestive Cancer
01/34
06/34
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
MOURA, Alexandre DE
GYNET, NCT04652076 / 2020-000172-38: GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting
1/2
240
Europe
NP137, Pembrolizumab, KEYTRUDA, Paclitaxel, Carboplatin
NETRIS Pharma, Merck Sharp & Dohme LLC, Centre Leon Berard
Endometrial Carcinoma, Cervix Carcinoma
10/25
07/26
FAP-IT, NCT06349512: 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer

Recruiting
N/A
60
Europe
68Ga-FAPI-46 PET/CT imaging
Institut Curie
Triple Negative Breast Cancer
11/27
11/27
AVATAR, NCT06459791: Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid

Recruiting
N/A
110
Europe
Biopsy, Line N+1 treatment recommandation
Institut Curie
Metastatic Breast Cancer
12/27
09/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DUBREUIL, Olivier
GASTFOX, NCT03006432: PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

Completed
3
507
Europe, RoW
Oxaliplatin, 5Fluorouracil bolus, 5Fluorouracil continu, Docetaxel, Folinic Acid
Federation Francophone de Cancerologie Digestive, UNICANCER, GERCOR - Multidisciplinary Oncology Cooperative Group
OESOPHAGO-GASTRIC CARCINOMA
02/25
02/25
ADAGE, NCT02355379: Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over

Recruiting
3
774
Europe
LV5FU2 or capectitabine, FOLFOX4 or XELOX, Observation, LV5FU2 or capecitabine
Federation Francophone de Cancerologie Digestive
Colonic Adenocarcinoma
12/24
08/25
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
AQUATIC, NCT04217447: Assessment of Quitting Versus Using Aspirin Therapy in Patients Treated with Oral Anticoagulation for Atrial Fibrillation or Other Indication with Stabilized Coronary Artery Disease

Terminated
3
874
Europe
OAC + Aspirin 100mg od, OAC + placebo of Aspirin 100mg od
University Hospital, Brest, Bayer
Coronary Artery Disease
10/24
10/24
SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting
2
99
Europe
MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil
GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG
Anal Cancer
02/23
12/24
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting
2
55
Europe
Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab
Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
09/24
09/24
FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting
2
400
Europe
FOLFOX regimen, CAPOX regimen
UNICANCER
Digestive Cancer, Colorectal Cancer
04/27
01/30
TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Recruiting
2
73
Europe
Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab
UNICANCER, Servier
Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency
10/26
10/28
PREMICES, NCT06646445: Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: Study.

Not yet recruiting
2
60
Europe
Pembrolizumab Injection [Keytruda], Keytruda, Watch-and-wait approach, Surgery, Adjuvant chemotherapy
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Colon Cancer
12/27
12/29
LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
BETTER 2, NCT03351296 / 2017-000741-46: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting
2
140
Europe
LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pancreatic Cancer
12/28
12/28
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting
2
78
Europe
Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Neuroendocrine Carcinoma, Digestive Cancer
01/34
06/34
COBRAF, NCT05639413: A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Recruiting
N/A
400
Europe
Collection of blood samples
UNICANCER, Pierre Fabre Medicament
Metastatic Colorectal Cancer, BRAF V600E Mutation Positive
07/27
07/28
MOURA, Alexandre DE
GYNET, NCT04652076 / 2020-000172-38: GYNecological Cancers Treated with NETrin MAbs in Combination with Chemotherapy and /or Pembrolizumab

Active, not recruiting
1/2
240
Europe
NP137, Pembrolizumab, KEYTRUDA, Paclitaxel, Carboplatin
NETRIS Pharma, Merck Sharp & Dohme LLC, Centre Leon Berard
Endometrial Carcinoma, Cervix Carcinoma
10/25
07/26
FAP-IT, NCT06349512: 68Ga-FAPI-46 PET/CT for Predicting Histological Response in Triple-negative Breast Cancer

Recruiting
N/A
60
Europe
68Ga-FAPI-46 PET/CT imaging
Institut Curie
Triple Negative Breast Cancer
11/27
11/27
AVATAR, NCT06459791: Efficacy of Personalized Tumorogram-based Therapy in Cancer Established From Patient-derived Organoid

Recruiting
N/A
110
Europe
Biopsy, Line N+1 treatment recommandation
Institut Curie
Metastatic Breast Cancer
12/27
09/28

Download Options